Cedric Francois, M.D., Ph.D., is a distinguished leader in the biopharmaceutical industry, currently serving as the President and Chief Executive Officer at Apellis Pharmaceuticals Inc. Dr. Francois has been instrumental in steering the company towards its mission of developing transformative therapies for diseases driven by the complement system. With a robust background in both medicine and science, he holds a medical degree from the Université Libre de Bruxelles and a Ph.D. in experimental medicine from KU Leuven, Belgium. His extensive training and expertise have been pivotal in guiding Apellis' research and development efforts. Under Dr. Francois's leadership, Apellis has made significant strides in advancing its pipeline of complement-targeted therapeutics. One of his notable achievements includes the successful development and approval of Empaveli (pegcetacoplan), a breakthrough treatment for paroxysmal nocturnal hemoglobinuria (PNH), which marked a significant milestone for the company and the broader medical community. His strategic vision and dedication to innovation have fostered a culture of excellence at Apellis, positioning the company as a leader in the complement therapeutics space. Dr. Francois continues to drive the company's growth, overseeing clinical trials and expanding the potential applications of Apellis' proprietary technology. In his role as President and CEO, Dr. Francois is committed to not only advancing scientific discovery but also ensuring that Apellis remains at the forefront of patient-centric care. His leadership extends beyond the company, as he actively engages with the scientific community to share insights and foster collaborations that can further the field of complement medicine. Dr. Francois's dual focus on scientific rigor and compassionate care underscores his holistic approach to leadership, making him a respected figure in the industry and a driving force behind Apellis Pharmaceuticals' ongoing success.